1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AstraZeneca Respiratory Head: Tezepelumab Could Be 'Game Changer'

 
• By Sten Stovall

AstraZeneca's first in class biologic tezepelumab, which targets TSLP, has revolutionary potential in treating severe asthma, the UK drug maker's respiratory head tells Scrip.

Asthama
Tezepelumab Likely To Enter Phase III Testing In Severe Asthma Late In 2017 Or Early 2018 • Source: Shutterstock

AstraZeneca PLC's ambitions to build a portfolio of cutting-edge respiratory therapies have been boosted by impressive data from a Phase IIb study which suggest its experimental biologic treatment tezepelumab could provide a more comprehensive approach to treating severe asthma than currently available.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.